Caplin Point Laboratories Ltd (CAPLIPOINT) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Caplin Point Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Analyst / investor Call for the quarter and half ended September 30, 2026
Intimation · 12 Nov 2026, 4:30 pm
Caplin Point Laboratories Schedules Q2 & H1 FY27 Earnings Call Caplin Point Laboratories will host its post-results earnings conference call on 12th Nov'26 at 16:30 IST to discuss its financial performance and business outlook for Q2 and H1 ended 30th Sep'26. Senior leadership, including Chairman C.C. Paarthipan, Managing Director Dr. Sridhar Ganesan, and CFO D. Muralidharan, will represent the company. Universal dial-in lines are available at +91 22 6280 1222 and +91 22 7115 8123, along with international toll-free access across key global regions.
CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 12 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 12 Nov 2026, 5:30 am
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve the unaudited financial ....
Intimation · 12 Nov 2026, 5:30 am
Caplin Point Laboratories Schedules Board Meeting on 12th Nov'26 for Q2 Financial Results Caplin Point Laboratories Limited announced that its Board of Directors will meet on 12th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with insider trading regulations, the trading window for dealing in company securities by designated persons and their immediate relatives remains closed from 1st Oct'26 through 14th Nov'26.
Voting Results and Scrutinizer Report for the 35th Annual General Meeting
Annual General Meeting · 26 Sept 2026, 12:43 am
Proceedings of 35th Annual General Meeting of the Company
Annual General Meeting · 25 Sept 2026, 8:57 pm
Clarification with respect to Volume Movement
Others (Uncategorized) · 25 Sept 2026, 7:35 pm
Caplin Point Clarifies Share Trading Volume Surge Is Purely Market Driven Caplin Point Laboratories clarified on 25th Sep'26 that the recent significant increase in share trading volume across exchanges is purely market driven. Responding to an inquiry from BSE, the company confirmed full compliance with Regulation 30 of SEBI LODR Regulations, affirming that no undisclosed material events, operational developments, or price-sensitive information have been withheld that could impact the stock's price or volume behavior.
The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Others (Uncategorized) · 25 Sept 2026, 6:55 pm
Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-26
Annual General Meeting · 04 Sept 2026, 8:26 pm
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Others (Uncategorized) · 03 Sept 2026, 6:24 pm
Caplin Point Laboratories FY26 ESG and Sustainability Report Highlights Caplin Point Laboratories released its BRSR for the year ended Mar'26, highlighting a surge in ESG-driven Capex to 23.49% of total Capex, up from 1.13% in FY25. The company consumed 1.15 crore KWh of renewable power, representing 36.65% of operations, and successfully recycled 52.39% of its water. Total Scope 1 and 2 emissions were contained at 3,524.56 and 13,875.64 metric tonnes of CO2 equivalent. Socially, the firm executed a CSR spend of ₹4.70 crores, reported zero workplace fatalities, and achieved 100% employee sensitization training on business ethics.
Notice of the 35th Annual General Meeting of the Company
Annual General Meeting · 03 Sept 2026, 6:16 pm
Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 03 Sept 2026, 6:07 pm
Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA
Others (Uncategorized) · 01 Sept 2026, 11:34 pm
Caplin Point Subsidiary Receives GMP Certification from Colombia's INVIMA Caplin Point Laboratories announced on Sep 01, '26 that its subsidiary, Caplin One Labs (COL), received Good Manufacturing Practices (GMP) compliance confirmation from Colombia's regulatory authority, INVIMA. The certification is for COL's manufacturing unit in Tamil Nadu, India. It covers the production of oncology drug products, including sterile lyophilized powder for injection (vials) and non-sterile tablets and capsules. This approval is a key regulatory milestone, facilitating market access and supply of these cancer treatments to Colombia. The formal certificate is expected shortly.
Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company''s subsidiary)
Others (Uncategorized) · 22 Aug 2026, 12:37 am
Caplin Steriles Receives 10 Observations in US FDA Inspection The US FDA concluded an unannounced inspection at Caplin Steriles' injectable and ophthalmic facility in Gummidipoondi on Aug 21, 2026. The inspection, which ran from Aug 13, resulted in a Form 483 with 10 observations. The company states the observations are procedural, do not involve data integrity issues, and none are repeat findings. Caplin Point is addressing the observations and will respond to the FDA within the stipulated timeframe.
Transcript for Earnings call- Q1- FY 2026-27
Transcript · 19 Aug 2026, 11:39 pm
Audio Recording of Earnings call for the Quarter ended June 30, 2026
Audio / Video · 13 Aug 2026, 12:16 am
Caplin Point Releases Q1 FY27 Earnings Call Audio Recording Caplin Point Laboratories has released the audio recording of its Q1 FY 2026-27 earnings call, which was held on 12 Aug'26. The recording is now available on the company's website, providing investors and analysts with direct access to management discussions regarding the quarterly performance and outlook. This follows the initial results communication on 30 Jul'26. The company is listed on the BSE (524742) and NSE (CAPLIPOINT).
Investor Presentation for the Earnings Call for the Quarter ended June 30, 2026.
Investor Presentation · 12 Aug 2026, 8:40 pm
Caplin Point Reports Strong Q1FY27; Announces Dividend & Key Appointments Caplin Point Laboratories reported strong Q1FY27 consolidated results with revenue at ₹643.9 Cr, up 20.7% YoY, and PAT at ₹179.1 Cr, up 18.8% YoY. Basic EPS grew 15.8% to ₹23.27. EBITDA margin expanded to 38.4% from 37.7% YoY. The Board recommended a final dividend of ₹4.00 per share for FY26, subject to approval. Key management changes include the re-appointment of Dr. Sridhar Ganesan as MD for two years and the appointment of Mr. D. Muralidharan (CFO) as Whole-Time Director, also for two years.
The Board of Director in its meeting held today, August 12, 2026, approved the appointment of directors.
Change in Management · 12 Aug 2026, 8:30 pm
Caplin Point Laboratories Announces Key Director Appointments Caplin Point's Board, on 12 Aug'26, re-appointed Dr. Sridhar Ganesan as Managing Director for a two-year term, from 25 Aug'26 to 24 Aug'28. Simultaneously, the Board appointed Mr. D. Muralidharan as a Whole-Time Director for a two-year term, effective 12 Aug'26 to 11 Aug'28. Mr. Muralidharan will continue to serve as the Chief Financial Officer (CFO), holding both key positions. Both appointments are subject to shareholder approval at the next Annual General Meeting (AGM).
Financial Results for the quarter ended June 30, 2026
Financial Result · 12 Aug 2026, 7:11 pm
Caplin Point Q1 FY27: Strong Revenue Growth and Margin Expansion Caplin Point reported strong Q1 FY27 consolidated results with revenue from operations at ₹610.4 Cr, up 19.6% YoY, and PAT at ₹179.1 Cr, up 18.8% YoY. EBITDA grew 23.0% YoY to ₹247.0 Cr, with the EBITDA margin expanding to 38.4% from 37.7% YoY. US market revenue rose 26% YoY to ₹137 Cr. Basic EPS increased to ₹23.27 from ₹20.10. The board recommended a final dividend of ₹4.00 per share for FY26. Key management changes include the re-appointment of Dr. Sridhar Ganesan as MD.
Record date for Final Dividend is September 18, 2026
Dividend · 12 Aug 2026, 7:06 pm
Caplin Point Labs Announces Record Date for AGM and Final Dividend Caplin Point Laboratories has scheduled its 35th Annual General Meeting (AGM) for Sep 25, '26. The company has fixed Fri, Sep 18, '26 as the record date for determining shareholder eligibility for the final dividend for FY26, if declared at the AGM. This applies to equity shares with a face value of Rs. 2 each. The board approved these dates at its meeting on Aug 12, '26.
Board meeting outcome for meeting held on August 12, 2026
Outcome · 12 Aug 2026, 7:02 pm
Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crores) ■ Revenue: 610 (+19.6% YoY | +1.7% QoQ) ■ EBITDA: 213 (+20.1% YoY | +4.5% QoQ) ■ EBITDA Margin (%): 35.0 (+14 bps YoY | +95 bps QoQ) ■ PAT: 177 (+15.8% YoY | +4.0% QoQ) ■ EPS (INR): 23.2 (+15.9% YoY | +4.0% QoQ) Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crores) Segmental Performance Rest of the World ■ Revenue: 476 (+18.0% YoY | +1.2% QoQ) ■ EBIT: 158 (+4.6% YoY | -3.0% QoQ) ■ EBIT Margin (%): 33.3 (-426 bps YoY | -146 bps QoQ) USA ■ Revenue: 134 (+25.9% YoY | +3.4% QoQ) ■ EBIT: 33.3 (+237.4% YoY | +52.9% QoQ) ■ EBIT Margin (%): 24.8 (+1553 bps YoY | +802 bps QoQ)
Post-results conference call invite for the quarter ended June 30, 2026 is enclosed herewith.
Intimation · 12 Aug 2026, 4:30 pm
Caplin Point Laboratories to Host Q1 FY27 Earnings Call on 12th Aug'26 Caplin Point Laboratories will host a conference call on 12th Aug'26 at 4:30 PM IST to discuss its financial performance for the quarter ended 30th Jun'26. The call is intended for analysts, fund houses, and investors. Senior management, including Chairman C.C. Paarthipan, Vice Chairmen Vivek and Ashok Partheeban, Managing Director Dr. Sridhar Ganesan, and CFO D. Muralidharan, will be present to detail the Q1 FY27 results and provide a business update. The event is organized by Dolat Capital.
Caplin Point Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....
Intimation · 12 Aug 2026, 5:30 am
Caplin Point Board to Consider Q1FY27 Results and Dividend on Aug 12 Caplin Point Laboratories has scheduled a board meeting on 12 Aug'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. The board will also discuss a recommendation for a final dividend for FY26 and fix the corresponding record date. Additionally, the agenda includes convening the 35th Annual General Meeting. The trading window for designated persons is closed from 01 Jul'26 to 14 Aug'26, inclusive, in compliance with insider trading regulations.
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation · 22 May 2026, 11:48 pm
Caplin Point to Meet Investors at TRINITY INDIA 2026 Conference Caplin Point Laboratories will participate in the 16th Annual Global Investor Conference, "TRINITY INDIA 2026," in Mumbai. Management is scheduled to meet with various analysts and institutional investors on 28 May'26, commencing at 10:00 AM. The interactions will consist of physical one-on-one and group meetings. The company noted that the schedule is subject to potential changes due to exigencies.
Transcript for Earnings call- Q4- FY 2025-26
Transcript · 21 May 2026, 11:51 pm